dc.contributor.author | Dolatabadi, JEN | |
dc.contributor.author | Azami, A | |
dc.contributor.author | Mohammadi, A | |
dc.contributor.author | Hamishehkar, H | |
dc.contributor.author | Panahi-Azar, V | |
dc.contributor.author | Saadat, YR | |
dc.contributor.author | Saei, AA | |
dc.date.accessioned | 2018-08-26T06:35:00Z | |
dc.date.available | 2018-08-26T06:35:00Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44116 | |
dc.description.abstract | Ketotifen (KT) as a second generation H1-antihistamine is used to relieve allergic conjunctivitis and allergies. To improve KT systemic bioavailability and reduce cellular toxicity, it was formulated into nanostructured lipid carriers (NLCs). KT-loaded NLCs were prepared using hot homogenization and ultrasonication methods and characterized using Zetasizer and transmission electron microscopy (TEM). The particle size and encapsulation efficiency (EE) of KT-loaded NLCs were around 100 nm and 70%, respectively. TEM image of NLCs revealed spherical shaped particles and verified the Zetasizer results. MTT and DAPI staining assays confirmed the low toxicity of KT-loaded NLCs. Finally, the prepared delivery system can be a surrogate for the traditionally available products used in the treatment of allergic symptoms. | |
dc.language.iso | English | |
dc.relation.ispartof | JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY | |
dc.subject | Nanostructured lipid carriers (NLCs) | |
dc.subject | Nanoparticle | |
dc.subject | Ketotifen fumarate | |
dc.subject | Encapsulation efficiency | |
dc.subject | Cytotoxicity | |
dc.title | Formulation, characterization and cytotoxicity evaluation of ketotifen-loaded nanostructured lipid carriers | |
dc.type | Article | |
dc.citation.volume | 46 | |
dc.citation.spage | 268 | |
dc.citation.epage | 273 | |
dc.citation.index | Web of science | |
dc.identifier.DOI | https://doi.org/10.1016/j.jddst.2018.05.017 | |